ertapenem 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
analogues of penicillanic acid antibiotics modified in the five-membered ring	1046	153832-46-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ertapenem invanz ertapenem sodium	Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Molecular weight: 475.52 Formula: C22H25N3O7S CLOGP: -0.83 LIPINSKI: 0 HAC: 10 HDO: 5 TPSA: 156.27 ALOGS: -3.22 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ertapenem
invanz
ertapenem sodium

Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3.

Molecular weight: 475.52
Formula: C22H25N3O7S
CLOGP: -0.83
LIPINSKI: 0
HAC: 10
HDO: 5
TPSA: 156.27
ALOGS: -3.22
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	38 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	28.72 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.45 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 18, 2002	EMA	Merck Sharp & Dohme Ltd
Nov. 21, 2001	FDA	MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	1105.60	25.25	293	6358	24083	63458288
Chronic sinusitis	236.41	25.25	77	6574	12766	63469605
Paraesthesia oral	216.90	25.25	80	6571	19176	63463195
Drug ineffective	200.45	25.25	374	6277	1044391	62437980
Procedural pain	193.85	25.25	76	6575	21493	63460878
Seizure	136.37	25.25	112	6539	132522	63349849
Vaginal flatulence	127.12	25.25	35	6616	3258	63479113
Proctitis	109.77	25.25	35	6616	5406	63476965
Hallucination	103.63	25.25	67	6584	54750	63427621
Female genital tract fistula	102.29	25.25	36	6615	7523	63474848
Product use in unapproved indication	100.41	25.25	108	6543	178972	63303399
Radiculopathy	97.71	25.25	36	6615	8575	63473796
Vaginal discharge	91.79	25.25	35	6616	9163	63473208
Dyspepsia	89.95	25.25	79	6572	102117	63380254
Encephalopathy	87.58	25.25	53	6598	38567	63443804
Therapeutic product effect incomplete	78.19	25.25	80	6571	124976	63357395
Confusional state	73.40	25.25	106	6545	236274	63246097
Oral candidiasis	69.63	25.25	38	6613	22760	63459611
Frequent bowel movements	63.81	25.25	36	6615	22986	63459385
Colitis ulcerative	62.22	25.25	37	6614	26054	63456317
Renal graft infection	61.00	25.25	12	6639	250	63482121
Pyrexia	59.28	25.25	143	6508	470335	63012036
Epilepsy	53.37	25.25	34	6617	27031	63455340
Mental status changes	50.40	25.25	38	6613	39561	63442810
Clostridium difficile infection	50.26	25.25	34	6617	29888	63452483
Avian influenza	47.75	25.25	8	6643	64	63482307
Colitis	45.63	25.25	39	6612	48489	63433882
Status epilepticus	45.43	25.25	25	6626	15208	63467163
Skin odour abnormal	43.23	25.25	13	6638	1653	63480718
Mitochondrial toxicity	42.96	25.25	10	6641	471	63481900
Clostridium test positive	42.36	25.25	15	6636	3186	63479185
Generalised tonic-clonic seizure	41.78	25.25	30	6621	28986	63453385
Rectal haemorrhage	41.27	25.25	37	6614	48993	63433378
Delirium	36.46	25.25	35	6616	50506	63431865
Weight decreased	35.65	25.25	85	6566	276713	63205658
Infusion related reaction	35.59	25.25	79	6572	245442	63236929
Drug reaction with eosinophilia and systemic symptoms	35.55	25.25	29	6622	33807	63448564
Acute generalised exanthematous pustulosis	35.27	25.25	19	6632	11080	63471291
Haematochezia	34.76	25.25	35	6616	53509	63428862
Wound secretion	33.62	25.25	14	6637	4600	63477771
Hallucination, visual	32.57	25.25	22	6629	19276	63463095
Tooth discolouration	31.48	25.25	9	6642	959	63481412
Bone marrow eosinophilic leukocyte count increased	30.82	25.25	5	6646	32	63482339
Fatigue	30.54	25.25	29	6622	887999	62594372
Seizure like phenomena	30.52	25.25	9	6642	1070	63481301
Arthralgia	30.26	25.25	11	6640	569699	62912672
Neurotoxicity	30.19	25.25	20	6631	16970	63465401
Allergic hepatitis	29.95	25.25	5	6646	39	63482332
Clostridium difficile colitis	29.00	25.25	21	6630	20548	63461823
Off label use	28.16	25.25	142	6509	674320	62808051
Klebsiella infection	28.16	25.25	15	6636	8551	63473820
Urinary tract infection pseudomonal	28.05	25.25	8	6643	845	63481526
Enterococcal infection	26.52	25.25	14	6637	7834	63474537
Pathogen resistance	26.23	25.25	13	6638	6385	63475986

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Confusional state	217.19	22.32	181	5413	143979	34807358
Seizure	203.63	22.32	153	5441	104704	34846633
Hallucination	134.00	22.32	90	5504	51408	34899929
Product use in unapproved indication	133.53	22.32	126	5468	117373	34833964
Encephalopathy	114.71	22.32	71	5523	35248	34916089
Pathogen resistance	102.47	22.32	43	5551	9439	34941898
Hallucination, visual	90.63	22.32	48	5546	17743	34933594
Delirium	86.83	22.32	65	5529	43926	34907411
Myoclonus	84.38	22.32	43	5551	14682	34936655
Epilepsy	66.67	22.32	42	5552	21453	34929884
Clostridium difficile colitis	65.07	22.32	37	5557	15693	34935644
Generalised tonic-clonic seizure	62.25	22.32	40	5554	21134	34930203
Toxic encephalopathy	50.72	22.32	22	5572	5227	34946110
Drug resistance	50.41	22.32	38	5556	25889	34925448
Status epilepticus	47.71	22.32	28	5566	12586	34938751
Serotonin syndrome	47.38	22.32	33	5561	19900	34931437
Drug reaction with eosinophilia and systemic symptoms	44.35	22.32	39	5555	32973	34918364
Biliary sepsis	44.26	22.32	12	5582	685	34950652
Neurotoxicity	43.23	22.32	30	5564	17980	34933357
Clostridium test positive	42.36	22.32	17	5577	3325	34948012
Disorientation	40.22	22.32	37	5557	33151	34918186
Agitation	39.04	22.32	47	5547	57352	34893985
Drug interaction	36.22	22.32	98	5496	225848	34725489
Myasthenia gravis crisis	36.13	22.32	10	5584	617	34950720
Neuromyopathy	35.34	22.32	11	5583	1023	34950314
Pseudomonal sepsis	34.70	22.32	15	5579	3532	34947805
Rash morbilliform	33.33	22.32	14	5580	3073	34948264
Eosinophilia	31.31	22.32	29	5565	26193	34925144
Appendicitis perforated	28.74	22.32	11	5583	1897	34949440
Conductive deafness	27.70	22.32	7	5587	303	34951034
Arterial angioplasty	26.72	22.32	5	5589	50	34951287
Neuropsychiatric symptoms	24.27	22.32	8	5586	894	34950443
Disorganised speech	24.24	22.32	8	5586	897	34950440
Mental status changes	23.96	22.32	30	5564	38053	34913284
Anticonvulsant drug level decreased	22.77	22.32	8	5586	1084	34950253
Vitamin A deficiency	22.41	22.32	4	5590	30	34951307

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	279.13	20.34	222	10910	188612	79544644
Confusional state	258.70	20.34	267	10865	317730	79415526
Hallucination	237.00	20.34	148	10984	85597	79647659
Macular degeneration	216.47	20.34	75	11057	11221	79722035
Chronic sinusitis	206.03	20.34	75	11057	12951	79720305
Product use in unapproved indication	204.72	20.34	211	10921	250148	79483108
Encephalopathy	192.92	20.34	119	11013	67278	79665978
Paraesthesia oral	183.04	20.34	78	11054	20393	79712863
Procedural pain	161.36	20.34	74	11058	23010	79710246
Epilepsy	121.57	20.34	74	11058	40786	79692470
Vaginal flatulence	121.09	20.34	34	11098	2541	79730715
Delirium	119.37	20.34	97	11035	84530	79648726
Hallucination, visual	114.99	20.34	66	11066	32663	79700593
Pathogen resistance	109.79	20.34	49	11083	14293	79718963
Myoclonus	105.87	20.34	59	11073	27601	79705655
Generalised tonic-clonic seizure	97.14	20.34	66	11066	43844	79689412
Female genital tract fistula	96.67	20.34	35	11097	5940	79727316
Clostridium difficile colitis	92.27	20.34	57	11075	32226	79701030
Proctitis	90.51	20.34	34	11098	6398	79726858
Status epilepticus	89.29	20.34	51	11081	24990	79708266
Clostridium test positive	86.77	20.34	33	11099	6421	79726835
Vaginal discharge	85.59	20.34	34	11098	7429	79725827
Radiculopathy	83.42	20.34	35	11097	8789	79724467
Drug reaction with eosinophilia and systemic symptoms	76.86	20.34	67	11065	64177	79669079
Neurotoxicity	72.20	20.34	49	11083	32469	79700787
Dyspepsia	70.04	20.34	81	11051	108606	79624650
Mental status changes	68.61	20.34	64	11068	66895	79666361
Toxic encephalopathy	65.56	20.34	32	11100	11408	79721848
Clostridium difficile infection	64.55	20.34	51	11081	42634	79690622
Pyrexia	61.65	20.34	221	10911	678488	79054768
Drug resistance	60.76	20.34	49	11083	42164	79691092
Oral candidiasis	54.96	20.34	40	11092	29588	79703668
Therapeutic product effect incomplete	48.97	20.34	78	11054	141567	79591689
Renal graft infection	48.70	20.34	12	11120	538	79732718
Fatigue	46.74	20.34	37	11095	929690	78803566
Disorientation	45.91	20.34	50	11082	62726	79670530
Frequent bowel movements	44.02	20.34	35	11097	29504	79703752
Avian influenza	43.24	20.34	8	11124	87	79733169
Granulomatous dermatitis	41.43	20.34	10	11122	411	79732845
Disorganised speech	40.32	20.34	14	11118	2103	79731153
Arthralgia	38.29	20.34	16	11116	571787	79161469
Eosinophilia	38.29	20.34	39	11093	45306	79687950
Off label use	37.46	20.34	235	10897	906980	78826276
Colitis ulcerative	37.10	20.34	34	11098	34708	79698548
Cross sensitivity reaction	36.01	20.34	15	11117	3697	79729559
Eosinophilic pneumonia	33.90	20.34	16	11116	5294	79727962
Agitation	33.20	20.34	54	11078	99661	79633595
Skin odour abnormal	32.62	20.34	12	11120	2129	79731127
Neuromyopathy	32.38	20.34	11	11121	1547	79731709
Biliary sepsis	31.98	20.34	11	11121	1606	79731650
Myasthenia gravis crisis	31.82	20.34	10	11122	1101	79732155
Tooth discolouration	31.42	20.34	10	11122	1147	79732109
Escherichia test positive	31.37	20.34	13	11119	3162	79730094
Seizure like phenomena	30.43	20.34	11	11121	1856	79731400
Conductive deafness	30.29	20.34	7	11125	238	79733018
Drug ineffective	29.65	20.34	254	10878	1080659	78652597
Bone marrow eosinophilic leukocyte count increased	29.25	20.34	5	11127	33	79733223
Acute generalised exanthematous pustulosis	29.09	20.34	22	11110	17232	79716024
Rash morbilliform	28.78	20.34	15	11117	6135	79727121
Allergic hepatitis	28.19	20.34	5	11127	42	79733214
Pain in extremity	28.17	20.34	8	11124	364530	79368726
Arterial angioplasty	27.40	20.34	5	11127	50	79733206
Urinary tract infection pseudomonal	27.10	20.34	10	11122	1788	79731468
Infusion related reaction	27.06	20.34	82	11050	230155	79503101
Colitis	26.18	20.34	41	11091	73266	79659990
Pseudomonal sepsis	25.90	20.34	14	11118	6160	79727096
Wound secretion	25.87	20.34	14	11118	6174	79727082
Colonic fistula	23.28	20.34	7	11125	665	79732591
Metabolic encephalopathy	23.24	20.34	15	11117	9132	79724124
Vitamin B1 deficiency	23.02	20.34	7	11125	691	79732565
Anticonvulsant drug level decreased	22.83	20.34	9	11123	1925	79731331
Enterococcal infection	22.15	20.34	18	11114	15642	79717614
Klebsiella infection	22.09	20.34	18	11114	15702	79717554
Hallucinations, mixed	21.80	20.34	13	11119	6886	79726370
Mitochondrial toxicity	21.80	20.34	10	11122	3104	79730152
Appendicitis perforated	21.38	20.34	10	11122	3243	79730013
Metabolic acidosis	21.35	20.34	40	11092	82489	79650767
Dyspnoea	21.31	20.34	56	11076	856969	78876287
Unresponsive to stimuli	21.04	20.34	32	11100	55756	79677500
Drug-induced liver injury	20.91	20.34	35	11097	66082	79667174
Haematochezia	20.85	20.34	41	11091	87604	79645652

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DH03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
FDA CS	M0024174	Carbapenems
FDA EPC	N0000175496	Penem Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute bacterial peritonitis	indication	31860008
Bacterial pneumonia	indication	53084003	DOID:874
Miscarriage with sepsis	indication	67465009
Haemophilus influenzae pneumonia	indication	70036007
Abdominal abscess	indication	75100008
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Pneumococcal pneumonia	indication	233607000
Escherichia coli urinary tract infection	indication	301011002
Community acquired pneumonia	indication	385093006
Peptostreptococcus infection	indication	135341000119101
Urinary tract infection caused by Klebsiella	indication	369001000119100
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection	indication
Septic Abortion due to Porphyromonas	indication
Post-Op Gynecologic Infection due to Porphyromonas	indication
Klebsiella Pyelonephritis	indication
Post-Op Gynecological Peptostreptococcus Infection	indication
Complicated E. Coli Peritonitis	indication
Postpartum Endomyometritis due to E. Coli	indication
Colorectal Surgery Infection Prevention	indication
Diabetic Foot Infection	indication
Streptococcal Septic Abortion	indication
Postpartum Endomyometritis due to Peptostreptococcus	indication
Post-Op Gynecologic Infection due to Bacteroides	indication
Postpartum Endomyometritis due to Bacteroides	indication
E. Coli Septic Abortion	indication
E. Coli Pyelonephritis	indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection	indication
Complicated Skin and Skin Structure E. Coli Infection	indication
Peptostreptococcus Septic Abortion	indication
Complicated Bacterial Peritonitis	indication
Complicated Bacteroides Peritonitis	indication
Moraxella Catarrhalis Pneumonia	indication
Post-Op Gynecologic Infection due to Prevotella	indication
Bacteroides Septic Abortion	indication
Post-Op Gynecological Infection due to E. Coli	indication
Postpartum Endomyometritis due to Porphyromonas	indication
Postpartum Endomyometritis due to Streptococcus	indication
Postpartum Endomyometritis due to Prevotella	indication
Post-Op Gynecologic Infection, due to Streptococcus	indication
Prevotella Septic Abortion	indication
Complicated Skin and Skin Structure Infection	indication
Gas gangrene caused by clostridium perfringens	off-label use	266093005
Clostridium Perfringens Empyema	off-label use
Acute nephropathy	contraindication	58574008
Kidney disease	contraindication	90708001	DOID:557
Seizure disorder	contraindication	128613002
Lesion of brain	contraindication	301766008
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.79	acidic
pKa2	4.1	acidic
pKa3	6.83	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Bioact source	MoA source
D-alanyl-D-alanine carboxypeptidase DacB	Enzyme	DACB_ECOLI	INHIBITOR	DRUGBANK	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_ECOLI	INHIBITOR	DRUGBANK	CHEMBL
Penicillin-binding protein 1B	Enzyme	PBPB_ECOLI	INHIBITOR	DRUGBANK	CHEMBL
Penicillin-binding protein 1	Enzyme	A1KS91_NEIMF		WOMBAT-PK
Penicillin-binding protein 2	Enzyme	Q9X6V3_PSEAI		WOMBAT-PK
D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6	Enzyme	Q7CHG0_YERPE		WOMBAT-PK
Penicillin-binding protein 4	Enzyme	Q5D1E9_STAAU		WOMBAT-PK
D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5	Enzyme	Q9X6V7_PSEAI		WOMBAT-PK

External reference:

ID	Source
4021283	VUID
N0000148720	NUI
D04049	KEGG_DRUG
153773-82-1	SECONDARY_CAS_RN
4021283	VANDF
C1120106	UMLSCUI
CHEBI:404903	CHEBI
6H7	PDB_CHEM_ID
CHEMBL1359	ChEMBL_ID
CHEMBL1232	ChEMBL_ID
D000077727	MESH_DESCRIPTOR_UI
DB00303	DRUGBANK_ID
10906	IUPHAR_LIGAND_ID
8049	INN_ID
G32F6EID2H	UNII
150610	PUBCHEM_CID
325642	RXNORM
16218	MMSL
173352	MMSL
274067	MMSL
42474	MMSL
d04783	MMSL
009554	NDDF
009555	NDDF
385573008	SNOMEDCT_US
385574002	SNOMEDCT_US
396346003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
INVANZ	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3843	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	28 sections
INVANZ	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3843	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	28 sections
INVANZ	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3845	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	NDA	28 sections
INVANZ	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3845	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	NDA	28 sections
ertapenem sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9398	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
ertapenem sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9398	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3510	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3510	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
ERTAPENEM SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	16714-889	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
ERTAPENEM SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	16714-889	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
ERTAPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	42023-221	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	29 sections
ERTAPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	42023-221	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	29 sections
ERTAPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	42023-221	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	29 sections
ERTAPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	42023-221	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	29 sections
ERTAPENEM	HUMAN PRESCRIPTION DRUG LABEL	1	42023-221	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	29 sections
ERTAPENEM SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	43598-901	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
ERTAPENEM SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	43598-901	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	44567-820	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	44567-820	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	28 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	44647-051	INJECTION	1 g	INTRAVENOUS	ANDA	29 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	44647-051	INJECTION	1 g	INTRAVENOUS	ANDA	29 sections
Ertapenem	Human Prescription Drug Label	1	55150-282	INJECTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	Human Prescription Drug Label	1	55150-282	INJECTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	Human Prescription Drug Label	1	55150-282	INJECTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	Human Prescription Drug Label	1	55150-282	INJECTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	Human Prescription Drug Label	1	55150-282	INJECTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	Human Prescription Drug Label	1	55150-282	INJECTION	1 g	INTRAVENOUS	ANDA	25 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6196	INJECTION	1 g	INTRAVENOUS	ANDA	29 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6196	INJECTION	1 g	INTRAVENOUS	ANDA	29 sections
Ertapenem	HUMAN PRESCRIPTION DRUG LABEL	1	63323-823	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	29 sections